|
000
| 01980nam 2200313za 4500 |
|---|
| 001 | 9.864450 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107161538 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 181108s1981 onc #ot f|0| 0 eng d |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 041 | |aeng|bfre |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aEC24-11/8-1981E-PDF |
|---|
| 100 | 1 |aGorecki, Paul K., |d1948- |
|---|
| 245 | 10|aRegulating the price of prescription drugs in Canada |h[electronic resource] : |bcompulsory licensing, product selection, and government reimbursement programmes / |cby Paul K. Gorecki. |
|---|
| 260 | |aOttawa : |bEconomic Council of Canada, |c1981. |
|---|
| 300 | |axiii, 300 p. : |bfigures, charts. |
|---|
| 490 | 1 |aTechnical report - Economic Council of Canada, |x0225-8013 ; |vno. 8 |
|---|
| 500 | |a"May 1981." |
|---|
| 500 | |aDigitized edition from print [produced by the Publishing and Depository Services Directorate]. |
|---|
| 504 | |aIncludes bibliographic references. |
|---|
| 520 | |a"The major findings of the study can be summarized as follows: prices have fallen, often substantially, at the level of the manufacturer for those drugs subject to licensee competition. These price reductions have been passed on to the consumer in the hospital market and, in varying degrees, in the provincial retail drug markets. It is not uncommon for expenditure on a particular licensed drug to be reduced by 50 percent from what it would have been without compulsory licensing and associated policy measures. Nevertheless further gains, often of considerable magnitude, can be achieved in virtually all markets"--Summary, p. xii. |
|---|
| 546 | |aIncludes abstract in French. |
|---|
| 692 | 07|2gccst|aPrescription drugs |
|---|
| 692 | 07|2gccst|aPrice regulation |
|---|
| 710 | 2 |aEconomic Council of Canada. |
|---|
| 830 | #0|aTechnical report (Economic Council of Canada)|x0225-8013 ; |vno. 8.|w(CaOODSP)9.855538 |
|---|
| 856 | 40|qPDF|s32.98 MB|uhttps://publications.gc.ca/collections/collection_2018/ecc/EC24-11-8-1981-eng.pdf |
|---|